Business Context and Reporting Period
Company: Alterity Therapeutics Limited (formerly Prana Biotechnology Limited)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 8, 2019
Reporting Period: Month of April 2019
Business Overview: The Company is a biotechnology firm developing small molecules to inhibit pathological protein aggregation in neurodegenerative diseases. Its lead candidate, PBT434, targets Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) by restoring iron balance in the brain.
Key Financial Metrics and Capital Structure
Capital Raise (Subscription): Completed a strategic investment by Life Biosciences LLC.
- Amount Raised: US$7.5 million (A$10.526 million).
- Shares Issued: 269,905,533 fully paid ordinary shares.
- Issue Price: A$0.039 per share.
- Warrants Issued: 539,811,066 two-for-one free-attaching warrants (Exercise Price: A$0.045; Expiry: December 19, 2019).
Capital Raise (Placement): Completed a private placement to unrelated investors.
- Amount Raised: A$913,807.
- Shares Issued: 23,430,949 fully paid ordinary shares.
- Warrants Issued: 46,861,898 two-for-one free-attaching warrants (same terms as Subscription).
Ownership Structure:
- Life Biosciences LLC holds a 31.35% relevant interest in voting shares.
- Potential interest for Life Biosciences could increase to 57.81% upon warrant exercise.
- Total ordinary shares on issue post-transaction: 860,837,432.
Financials: The filing does not provide specific revenue, profit, cash flow, or margin data. The Company is in the research and development phase.
Material Changes
- Corporate Name Change: The Company changed its name from Prana Biotechnology Limited to Alterity Therapeutics Limited.
- Board Composition:
- Appointments: Dr. David Sinclair and Mr. Tristan Edwards joined the Board.
- Resignations: Prof. Ira Shoulson and Dr. George Mihaly resigned.
- Lock-Up Agreements: Continuing directors and officers entered into lock-up letters for 18,592,577 shares and 10,250,000 options until August 16, 2019.
- Escrow: Shares and warrants issued to Life Biosciences are voluntarily escrowed until registered with the SEC or otherwise tradable in the US.
Guidance, Outlook, and Risks
Management Commentary: CEO Geoffrey Kempler stated the investment provides funding for "several years" to advance clinical programs, describing the change as "transformational."
Use of Proceeds: Funds are proposed for research and development of product candidates and other compounds.
Future Capital Rights: Life Biosciences holds a "Come-along Right" to participate in future capital raisings to maintain its ownership percentage (lapsing December 19, 2019).
Risks and Contingencies:
- Warrant Exercise: No assurance that warrants issued to Life Biosciences will be exercised.
- Development Risks: Risks include delays in clinical trials, regulatory approval, and potential adverse side effects or inadequate efficacy of PBT434.
- Financing: Uncertainty regarding the ability to procure additional future financing.
- Intellectual Property: Uncertainty regarding patent protection for drug components.
Key Facts for Investor Verification
- Verify the new ticker symbols (anticipated ASX:ATH and Nasdaq:ATHE) and trading commencement dates.
- Confirm the exact dilution impact on existing shareholders given the issuance of ~293 million new shares and ~586 million warrants.
- Monitor the exercise of warrants by Life Biosciences, which could significantly alter the ownership structure (up to 57.81% interest).
- Review the specific clinical trial timelines and milestones for PBT434 to assess the runway provided by the A$11.4 million raised.
- Check for any subsequent filings regarding the registration of Life Biosciences' shares with the SEC to determine when escrow restrictions lift.